Discovery methods of coagulation-inhibiting drugs

被引:23
作者
Gomez-Outes, Antonio [1 ]
Garcia-Fuentes, Minerva [1 ]
Luisa Suarez-Gea, Ma [1 ]
机构
[1] Spanish Agcy Med & Med Devices AEMPS, Div Pharmacol & Clin Drug Evaluat Med Human Use, Parque Empresaria Las Mercedes,Edificio 8, Madrid 28022, Spain
关键词
Stroke; anticoagulant; discovery; thrombosis; bleeding; PATIENTS ANTITHROMBOTIC THERAPY; FACTOR XIA INHIBITORS; ED AMERICAN-COLLEGE; VENOUS THROMBOEMBOLISM; ANTISENSE OLIGONUCLEOTIDES; INORGANIC POLYPHOSPHATE; ALLOSTERIC INHIBITION; THROMBIN GENERATION; INTRINSIC PATHWAY; IN-VITRO;
D O I
10.1080/17460441.2017.1384811
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: In the last decade, several direct oral anticoagulants (DOAC) targeting thrombin (dabigatran) or activated factor X (FXa) (rivaroxaban, apixaban and edoxaban) have been marketed for a number of indications related to prophylaxis and treatment of thrombotic diseases. All these drugs are effective in preventing thrombosis, but are associated with an increased bleeding risk.Areas covered: This review includes a summary of new targets for anticoagulation (e.g.: FXIa, FXIIa, protein disulfide isomerase, polyphosphates, etc.), the discovery process and pharmacological features of new anticoagulant compounds and the available results from non-clinical and clinical studies. A significant number of new anticoagulant compounds are currently in development. These compounds were developed using different technologies like SELEX (aptamers), antisense technology (ASOs), hybridoma (MAB) and structure based drug design. Compounds like ichorcumab (a parenteral thrombin inhibitor), BMS-986177 (oral FXIa inhibitor), BAY-1213790 and xisomab (parenteral FXIa inhibitors) are currently in the clinical development stage.Expert opinion: It's important to be cautious when interpreting preliminary findings of new compounds showing a good antithrombotic effect without altering haemostasis. That being said, the anticoagulants in development have the potential to provide a safer alternative to the currently available anticoagulants in patients at high risk of bleeding, but further investigation is warranted.
引用
收藏
页码:1195 / 1205
页数:11
相关论文
共 96 条
[31]   The discovery of dabigatran etexilate for the treatment of venous thrombosis [J].
Feuring, Martin ;
van Ryn, Joanne .
EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (07) :717-731
[32]   DU-176b, a potent and orally active factor Xa inhibitor:: in vitro and in vivo pharmacological profiles [J].
Furugohri, T. ;
Isobe, K. ;
Honda, Y. ;
Kamisato-Matsumoto, C. ;
Sugiyama, N. ;
Nagahara, T. ;
Morishima, Y. ;
Shibano, T. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (09) :1542-1549
[33]   Factor XI and contact activation as targets for antithrombotic therapy [J].
Gailani, D. ;
Bane, C. E. ;
Gruber, A. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (08) :1383-1395
[34]   Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management [J].
Galabova, Gergana ;
Brunner, Sylvia ;
Winsauer, Gabriele ;
Juno, Claudia ;
Wanko, Bettina ;
Mairhofer, Andreas ;
Luehrs, Petra ;
Schneeberger, Achim ;
von Bonin, Arne ;
Mattner, Frank ;
Schmidt, Walter ;
Staffler, Guenther .
PLOS ONE, 2014, 9 (12)
[35]   Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives [J].
Gomez-Outes, Antonio ;
Luisa Suarez-Gea, M. ;
Lecumberri, Ramon ;
Isabel Terleira-Fernandez, Ana ;
Vargas-Castrillon, Emilio .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (05) :389-404
[36]  
Gomez-Outes Antonio, 2012, Curr Drug Discov Technol, V9, P83
[37]   Idarucizumab for the Reversal of Dabigatran [J].
Gottlieb, Michael ;
Khishfe, Basem .
ANNALS OF EMERGENCY MEDICINE, 2017, 69 (05) :554-558
[38]   Prevention of VTE in Nonorthopedic Surgical Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].
Gould, Michael K. ;
Garcia, David A. ;
Wren, Sherry M. ;
Karanicolas, Paul J. ;
Arcelus, Juan I. ;
Heit, John A. ;
Samama, Charles M. .
CHEST, 2012, 141 (02) :E227S-E277S
[39]   Neutralization of EP217609, a new dual-action FIIa/FXa anticoagulant, by its specific antidote avidin: a phase I study [J].
Gueret, P. ;
Combe, S. ;
Krezel, C. ;
Fuseau, E. ;
van Giersbergen, P. L. M. ;
Petitou, M. ;
Neuhart, E. .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (01) :15-28
[40]   Inorganic polyphosphate: a key modulator of inflammation [J].
Hassanian, S. M. ;
Avan, A. ;
Ardeshirylajimi, A. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (02) :213-218